{'fraction_non_alphanumeric': 0.04250295159386069, 'fraction_numerical': 0.025974025974025976, 'mean_word_length': 5.281481481481482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Utility evaluation and radio‐pathological analysis of a tau tracer, 18F‐PI‐2620, in Alzheimer’s disease (AD) and non‐AD tauopathies

Tau aggregates are one of key pathological features of Alzheimer's disease (AD) and other neurodegenerative diseases. Recently, PET probes for tau have been developed for in vivo detection of tau accumulation, but have limitations such as off‐target binding and lower ability to detect tau in non‐AD tauopathies. Preclinically, a tau tracer, 18F‐PI‐2620, has a high binding‐affinity and specificity for aggregated tau, and was indicated to have desirable properties for visualization of tau accumulation in both AD and non‐AD tauopathies (Kroth H. et al, Eur J Nucl Med Mol Imaging, 2019). The aim of present study is to assess the ability of 18F‐PI‐2620 to detect regional tau burden in AD and non‐AD tauopathies.